Google

Sunday, April 27, 2008

Abilify for the Kids

Bristol-Myers Squibb released their earnings last week. No real news on the Abilify front. It continues to grow year over year and now has the pediatric bipolar and adolescent schizophrenia indications in its pocket to be the kid-friendly atypical anti-psychotic. Analysts didn't really press on Abilify since the Mead Johnson IPO idea started all their wheels turning.

Guess we can look for the Abilify reps in our pediatrician's office the next time the kids' need a sports physical.

Wednesday, April 16, 2008

Just How Bad is it for Invega / Teva's Generic Risperidone

For the past couple of earnings calls, JNJ has been hiding the Invega debacle within their Risperdal numbers by reporting the total sales of Risperdal and Invega together. Yesterday they switched strategy and instead hid Invega in the Other category. That's rich. Here's the relevant details from the conference call. Watch as they duck and weave the analyst's request to get to the Invega numbers...

Glenn Reicin - Morgan Stanley
That’s very helpful. Okay, and then also just two other quick questions -- INVEGA, is that included in the RISPERDAL number or is that separate now?
Dominic J. Caruso
That’s separate now in Other.
Glenn Reicin - Morgan Stanley
Okay, and you are not going to tell us what that number is?
Louise Mehrotra
No, not right now.
Glenn Reicin - Morgan Stanley
Okay, so all the other numbers you’ve given us in the past are going to be restated for that change?
Louise Mehrotra
The numbers that you have in the schedule have your comparables for prior year.
Glenn Reicin - Morgan Stanley
In prior quarters did INVEGA, was that included under the anti-psychotic number?
Louise Mehrotra
Yes, it was. And the numbers --
Glenn Reicin - Morgan Stanley
Okay, so we’re going to get restated schedules for all of the quarters going back or no?
Louise Mehrotra
What we have given you here is 2007 restated to take INVEGA out. We certainly could give you -- break out the RISPERDAL Oral and we could put that up.

Hahahahaha Ridiculous. Full transcript available here.

The good news for JNJ is that it looks like Teva will get the 6 month exclusivity on generic risperidone. Good news because JNJ can keep the generic price higher with only one other player in the market. The price for the generic will thus likely bottom out at the beginning of 2009 given current expectations for multiple entrants.